LONDON, UK / ACCESSWIRE / April 10, 2024 / TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BP2C3V08
Issuer Name
GENFLOW BIOSCIENCES PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Premier Miton Group plc
City of registered office (if applicable)
GUILDFORD
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
09-Apr-2024
6. Date on which Issuer notified
09-Apr-2024
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was crossed or reached |
9.150527 |
0.000000 |
9.150527 |
32000000 |
Position of previous notification (if applicable) |
N/A |
|
N/A |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 |
|
32000000 |
|
9.150527 |
Sub Total 8.A |
32000000 |
9.150527% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
|
|
|
Sub Total 8.B1 |
|
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
|
||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
Premier Miton Group plc |
Premier Miton Group Plc (Chain 1) |
|
|
|
Premier Miton Group plc |
Premier Asset Management Midco Ltd (Chain 1) |
|
|
|
Premier Miton Group plc |
Premier Asset Management Holdings Ltd (Chain 1) |
|
|
|
Premier Miton Group plc |
Premier Asset Management Limited (Chain 1) |
|
|
|
Premier Miton Group plc |
Premier Investment Group Ltd (Chain 1) |
|
|
|
Premier Miton Group plc |
Premier Fund Managers Ltd (Chain 1) |
9.150527 |
|
9.150527% |
Premier Miton Group plc |
Premier Miton Group Plc (Chain 2) |
|
|
|
Premier Miton Group plc |
Premier Asset Management Midco Ltd (Chain 2) |
|
|
|
Premier Miton Group plc |
Tellworth Investments LLP (Chain 2) |
|
|
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
09-Apr-2024
13. Place Of Completion
Guildford, UK
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on accesswire.com
